The new company will use Seer's Proteograph proteomic platform along with other omics data to develop and commercialize tests for cancer and other diseases.
Formerly the data analytics division of CTCA, Vidence is supporting an immuno-oncology trial for BMS as it looks to grow its network of hospital partners.
The firm presented a poster at ASCO suggesting that its StemPrintER platform outperforms Exact Science's Oncotype Dx for predicting breast cancer recurrence.
The University of Utah spinout said it will use the funding to enhance and expand its NGS-based Explify microbe identification platform and support its lab.
